All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Johnson & Johnson, Kura Oncology, Roche, Syndax and Thermo Fisher, and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

2023-07-04T10:07:10.000Z

Optimizing transplant outcomes in patients allografted for AML

Bookmark this article

During the AML Hub Steering Committee meeting held on May 17, 2023, Charles Craddock chaired a discussion on optimizing transplant outcomes in patients allografted for acute myeloid leukemia, with contributions from Gail Roboz, Selina Luger, Jorge Sierra, Naval Daver, and Jeffrey Lancet.

Optimizing transplant outcomes in patients allografted for AML

Craddock discusses the optimal selection of patients for transplant and strategies to improve outcomes in patients who are candidates for transplant, with a particular focus on conditioning regimens. He highlights the US-CTN 0901 study comparing myeloablative conditioning (MAC) and reduced-intensity conditioning (RIC) regimens and the FIGARO trial assessing intensified RIC regimens. The committee discusses the timing and selection of patients for transplant and the difference in patients’ and clinicians’ perceptions of the chance of a cure. They also discuss the need for randomized trials assessing transplantation and factors that affect transplant outcomes, the optimal design of these trials, and the value of data sharing between centers. They raise the need for the standardization of the status of patients going to transplant.

More about...

Your opinion matters

HCPs, what is your preferred format for educational content on the AML Hub?
29 votes - 46 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox